Obesity and cancer immunotherapy toxicity

American Society of Clinical Oncology Position Statement on Obesity and Cancer

(2014) Jennifer A. Ligibel et al.   JOURNAL OF CLINICAL ONCOLOGY

Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice

(2014) Annie Mirsoian et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mitigating the toxic effects of anticancer immunotherapy

(2014) Tara C. Gangadhar et al.   Nature Reviews Clinical Oncology

Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy

(2013) Myriam N. Bouchlaka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunological complications of obesity

(2012) Thirumala-Devi Kanneganti et al.   NATURE IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor Therapy for B-cell Malignancies

(2012) David L Porter et al.   Journal of Cancer

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY